Primary Insomnia Clinical Trial
Official title:
The RCT Study on the Evaluation of Clinical Effect of Primary Insomnia Treated With the Tiaoshen Acupuncture
Through the recruition of outpatients who clinically meet the diagnostic criteria and inclusion criteria of PI, the acupuncture group adopts Tiaoshen acupuncture, and the placebo acupuncture group adopts non-insertive acupuncture supported by the Park device, and the Pittsburgh Sleep Quality Index (PSQI) is used as the main index to evaluate the patients through the scale; subjective indicators like Chalder 14-item fatigue scale, Epworth sleepiness rating, self-rating anxiety scale (SAS), self-rating depression scale (SDS) and objective indicators like polysomnography (PSG), heart rate variability (HRV) is regarded as a secondary index, and then evaluate the clinical efficacy of Tiaoshen acupuncture on PI and explore its mechanism.
Status | Recruiting |
Enrollment | 84 |
Est. completion date | December 31, 2025 |
Est. primary completion date | June 1, 2025 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 70 Years |
Eligibility | Inclusion Criteria: - Conforming to the diagnostic criteria of traditional Chinese and Western medicine for chronic insomnia; - Age range: 18-70 years old; - PSQI score>7 points; SAS score > 50 or SDS score > 53; - No communication and cognitive impairment; - No use or withdrawal of psychoactive drugs such as anti-anxiety within one month; ·No major physical diseases; - Those who voluntarily accept the research content and can complete various scale evaluations, polysomnography monitoring and HRV; - Sign an informed consent form prior to the start of the study. Exclusion Criteria: - Those who do not meet the inclusion criteria; - Persons with a history of severe mental illness, severe head injury, and significant disturbance of consciousness; - Those with severe liver and renal insufficiency and bleeding tendencies; - Alcoholism (liquor = 100ml/day), smoking (= 15 cigarettes/day), drug abuse or taking psychotropic drugs; - People with other sleep disorders, such as sleep apnea hypopnea syndrome, paroxysmal sleeping sickness, and REM sleep behavioral disorders; - Pregnant or nursing; - Those with other major diseases and poor control; - Other persons who are unwilling to sign informed consent. |
Country | Name | City | State |
---|---|---|---|
China | The Third Affiliated Hospital of Zhejiang Chinese Medical University | Hangzhou | Zhejiang |
Lead Sponsor | Collaborator |
---|---|
The Third Affiliated hospital of Zhejiang Chinese Medical University |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Pittsburgh sleep quality index | Use the PSQI score table to evaluate according to patient's situation, and analyze the score changes of the subjects' insomnia degree before and after treatment by the analysis of score data. The PSQI consists of 19 self-rated questions and 5 questions rated by sleep partners. The 19 self-assessment questions constitute 7 factors ranging from 0 to 3 points. The cumulative score of each factor component is the total score of the PSQI, and the total score ranges from 0 to 21. The higher the score, the worse the sleep quality. | Before treatment | |
Primary | Pittsburgh sleep quality index | Use the PSQI score table to evaluate according to patient's situation, and analyze the score changes of the subjects' insomnia degree before and after treatment by the analysis of score data. The PSQI consists of 19 self-rated questions and 5 questions rated by sleep partners. The 19 self-assessment questions constitute 7 factors ranging from 0 to 3 points. The cumulative score of each factor component is the total score of the PSQI, and the total score ranges from 0 to 21. The higher the score, the worse the sleep quality. | the 4th week of treatment | |
Primary | Pittsburgh sleep quality index | Use the PSQI score table to evaluate according to patient's situation, and analyze the score changes of the subjects' insomnia degree before and after treatment by the analysis of score data.The PSQI consists of 19 self-rated questions and 5 questions rated by sleep partners. The 19 self-assessment questions constitute 7 factors ranging from 0 to 3 points. The cumulative score of each factor component is the total score of the PSQI, and the total score ranges from 0 to 21. The higher the score, the worse the sleep quality. | 4 weeks after treatment | |
Secondary | Fatigue Scale-14 | Respond to the severity of fatigue from different angles through 14 questions.The Fatigue Scale-14 is composed of 14 items, and the 14 items are divided into two categories. One category reflects physical fatigue, including 1 to 8 items; the other reflects mental fatigue, including 9 to 14 in total 6 items. The highest score for physical fatigue is 8, the highest score for mental fatigue is 6, and the highest total score is 14. The higher the score, the more severe the fatigue. | Before treatment | |
Secondary | Fatigue Scale-14 | Respond to the severity of fatigue from different angles through 14 questions.The Fatigue Scale-14 is composed of 14 items, and the 14 items are divided into two categories. One category reflects physical fatigue, including 1 to 8 items; the other reflects mental fatigue, including 9 to 14 in total 6 items. The highest score for physical fatigue is 8, the highest score for mental fatigue is 6, and the highest total score is 14. The higher the score, the more severe the fatigue. | the 4th week of treatment | |
Secondary | Fatigue Scale-14 | Respond to the severity of fatigue from different angles through 14 questions.The Fatigue Scale-14 is composed of 14 items, and the 14 items are divided into two categories. One category reflects physical fatigue, including 1 to 8 items; the other reflects mental fatigue, including 9 to 14 in total 6 items. The highest score for physical fatigue is 8, the highest score for mental fatigue is 6, and the highest total score is 14. The higher the score, the more severe the fatigue. | 4 weeks after treatment | |
Secondary | Epworth Sleepiness Scale | The epworth sleepiness scale is applied to assess excessive daytime sleepiness. The clinical significance of this table is: sleepiness can be semi-objectively assessed by the epworth sleepiness scale. Any sleep disorder caused by sleep deprivation may lead to change of this scale. This scale has 24 points. A score greater than 6 indicates drowsiness, a score greater than 11 indicates excessive sleepiness, and a score greater than 16 indicates dangerous drowsiness. | Before treatment | |
Secondary | Epworth Sleepiness Scale | The epworth sleepiness scale is applied to assess excessive daytime sleepiness. The clinical significance of this table is: sleepiness can be semi-objectively assessed by the epworth sleepiness scale. Any sleep disorder caused by sleep deprivation may lead to change of this scale. This scale has 24 points. A score greater than 6 indicates drowsiness, a score greater than 11 indicates excessive sleepiness, and a score greater than 16 indicates dangerous drowsiness. | he 4th week of treatment | |
Secondary | Epworth Sleepiness Scale | The epworth sleepiness scale is applied to assess excessive daytime sleepiness. The clinical significance of this table is: sleepiness can be semi-objectively assessed by the epworth sleepiness scale. Any sleep disorder caused by sleep deprivation may lead to change of this scale. This scale has 24 points. A score greater than 6 indicates drowsiness, a score greater than 11 indicates excessive sleepiness, and a score greater than 16 indicates dangerous drowsiness. | 4 weeks after treatment | |
Secondary | Self-Rating Anxiety Scale | SAS is called anxiety self-rating scale, which is a standard for anxiety assessment and a psychological scale used to measure the degree of anxiety state and its changes during treatment. The SAS scale has 100 points in total, and the cut-off value is 50 points, of which 50-59 points are mild anxiety, 60-69 points are moderate anxiety, and more than 70 points are severe anxiety. | Before treatment | |
Secondary | Self-Rating Anxiety Scale | SAS is called anxiety self-rating scale, which is a standard for anxiety assessment and a psychological scale used to measure the degree of anxiety state and its changes during treatment. The SAS scale has 100 points in total, and the cut-off value is 50 points, of which 50-59 points are mild anxiety, 60-69 points are moderate anxiety, and more than 70 points are severe anxiety. | 4th week of treatment | |
Secondary | Self-Rating Anxiety Scale | SAS is called anxiety self-rating scale, which is a standard for anxiety assessment and a psychological scale used to measure the degree of anxiety state and its changes during treatment. The SAS scale has 100 points in total, and the cut-off value is 50 points, of which 50-59 points are mild anxiety, 60-69 points are moderate anxiety, and more than 70 points are severe anxiety. | 4 weeks after treatment | |
Secondary | Self-rating depression scale | The depression self-rating scale is a standard for depression assessment, which can quite intuitively reflect the subjective feelings of depressed patients during treatment. It is mainly applicable to adults with depressive symptoms, including outpatients and inpatients. The SDS scale has 100 points in total, and the cut-off value is 53 points, of which 53-62 points are mild anxiety, 63-72 points are moderate anxiety, and more than 73 points are severe anxiety. | Before treatment | |
Secondary | Self-rating depression scale | The depression self-rating scale is a standard for depression assessment, which can quite intuitively reflect the subjective feelings of depressed patients during treatment. It is mainly applicable to adults with depressive symptoms, including outpatients and inpatients. The SDS scale has 100 points in total, and the cut-off value is 53 points, of which 53-62 points are mild anxiety, 63-72 points are moderate anxiety, and more than 73 points are severe anxiety. | the 4th week of treatment | |
Secondary | Self-rating depression scale | The depression self-rating scale is a standard for depression assessment, which can quite intuitively reflect the subjective feelings of depressed patients during treatment. It is mainly applicable to adults with depressive symptoms, including outpatients and inpatients. The SDS scale has 100 points in total, and the cut-off value is 53 points, of which 53-62 points are mild anxiety, 63-72 points are moderate anxiety, and more than 73 points are severe anxiety. | 4 weeks after treatment | |
Secondary | Polysomnography | Polysomnography refers to the continuous and synchronous acquisition, recording and analysis of EEG, electrooculogram, electromyogram, oronasal airflow, respiratory effort, and saturation of oxygen levels, body position and other physiological and pathological parameters during sleep by sleep technicians all night through computer software in the sleep laboratory. This technology for the diagnosis of sleep disorders is the gold standard for the diagnosis and treatment of sleep disorders. | the 4th week of treatment | |
Secondary | Heart rate variability | Heart rate variability (HRV) refers to the fluctuations in the interval between successive heartbeats. It is commonly used to evaluate the regulatory role of the autonomic nervous system on cardiac activity. It is an important noninvasive indicator for evaluating autonomic nervous activity, and is also one of the important indicators for evaluating autonomic nervous changes during sleep. | the 4th week of treatment |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT03461666 -
Comparison of Efficacy of Behavioral Approaches for Treatment of Insomnia
|
N/A | |
Recruiting |
NCT02243501 -
Better Nights, Better Days for Typically Developing Children
|
N/A | |
Completed |
NCT01636791 -
CBT Versus a Return to Work Intervention for Patients With Common Mental Illness in Primary Care
|
Phase 3 | |
Completed |
NCT00770510 -
A Phase II/III Study of SEP-190 (Eszopiclone) in Patients With Primary Insomnia (Study 190-126)
|
Phase 2/Phase 3 | |
Completed |
NCT00520832 -
A Pilot Study Of The Effects Of Microcurrent On Three Sleep Surveys
|
Phase 2 | |
Recruiting |
NCT00415714 -
Safety and Efficacy of an Ambulatory Biofeedback Device for Primary Insomnia
|
N/A | |
Terminated |
NCT00420810 -
Adult Polysomnography Primary Insomnia Cross Over Study (0928-049)(TERMINATED)
|
Phase 3 | |
Completed |
NCT00178048 -
Paroxetine in the Treatment of Chronic Primary Insomnia
|
Phase 4 | |
Completed |
NCT00816673 -
Sleep Inducing And Maintaining Efficacy Of Circadin In Elderly Insomniacs
|
Phase 2 | |
Completed |
NCT01957111 -
Metabolomics of Insomnia-Related Hyperarousal
|
N/A | |
Completed |
NCT01960452 -
A High Density EEG Comparison of Sleep Patterns in Insomnia
|
N/A | |
Completed |
NCT01181232 -
A Study to Compare Efficacy and Safety of Zolpidem Modified Release Formulation Versus Zolpidem in Insomnia Patients
|
Phase 4 | |
Completed |
NCT00784875 -
An Efficacy Study of Compound LY2624803 in the Treatment of Patients With Chronic Insomnia
|
Phase 2 | |
Completed |
NCT00551148 -
A Dose-ranging, Multicenter Polysomnography Trial of PD 0200390 in Adults With Primary Insomnia
|
Phase 2 | |
Completed |
NCT00397189 -
Efficacy and Safety of Circadin® 2 mg in the Treatment of Primary Insomnia Patients
|
Phase 3 | |
Completed |
NCT00352144 -
6-Month Chronic Efficacy & Safety Study of Eszopiclone in Adult Subjects With Primary Insomnia
|
Phase 3 | |
Completed |
NCT02290405 -
Impact of Hyperarousal on Simple and Complex Cognitive Task Performance Among Insomnia Sufferers
|
||
Completed |
NCT03314441 -
Effects of Regular Practice of Yoga on Subjective and Objective Sleep Quality in Primary Insomnia
|
N/A | |
Completed |
NCT00792298 -
Phase IIB 2-Period Crossover Polysomnography Study in Participants With Primary Insomnia (MK-4305-006)
|
Phase 2 | |
Completed |
NCT01021852 -
Polysomnography Study of MK-6096 in Participants With Primary Insomnia (MK-6096-011)
|
Phase 2 |